OncoArendi Therapeutics

OncoArendi Therapeutics is rated 3 out of 5 in the category better medicines inspired by science. Read and write reviews about OncoArendi Therapeutics. OncoArendi Therapeutics is a biotech, public company based in Poland focused on discovery & development of small molecules to treat patients with unmet medical needs. OncoArendi intends to realize the full potential of its drug candidates through collaboration, co-development and licensing assets to external partners. OncoArendi’s business model is strictly focused on drug discovery and development, with its core strength in high quality medicinal chemistry and preclinical biology, enhanced by scientific collaborations with the key opinion leaders in specific disease areas and prudent use of CROs. OncoArendi currently employs 90 people, the majority of whom hold PhD degrees in biology and chemistry. Researchers at OncoArendi study the therapeutic potential of chitinases, chitinase-like-proteins (CLPs) which provide multiple points for therapeutic intervention. OncoArendi currently has a platform of 3 distinct small molecule programs targeting chitinases and CLPs, with potential utility in diverse inflammatory and fibrotic diseases of high unmet medical need (IPF, sarcoidosis, asthma, NASH). The most advanced compound from chitinase platform - OATD-01, a drug developed in inflammation-driven fibrotic diseases currently completing phase Ib of clinical development. Further to that, and in close collaboration with several leading academic and clinical institutions and industrial partners, OncoArendi has initiated a program focused on development of small molecule immune-modulators to knock down the ability of tumors to escape immune surveillance. These unique, proprietary compounds will target a strategic enzyme involved in amino-acid metabolism -arginase, that allows tumor cells to hamper antitumor immunity and to avoid immune surveillance. OncoArendi's arginase inhibitor - OATD-02, for cancer immunotherapy, currently completing IND-enabling studies.